Brain TRPV1: a depressing TR(i)P down memory lane?

Trends in Pharmacological Sciences

Volumn 29, Issue 12, 2008, Pages 594-600

  Di Marzo, Vincenzo ^a   Gobbi, Gabriella ^b,c   Szallasi, Arpad ^d  

^a CNR   (Italy)

^b MCGILL UNIVERSITY   (Canada)

^c CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^d MONMOUTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANALGESIC AGENT; ANANDAMIDE; ANTIDEPRESSANT AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CAPSAICIN; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DESIPRAMINE; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; FLUOXETINE; LITHIUM; MIANSERIN; OLVANIL; OPIATE; RECEPTOR BLOCKING AGENT; RIMONABANT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TARANABANT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST;

ALZHEIMER DISEASE; ANALGESIA; ANIMAL BEHAVIOR; ANTINOCICEPTION; ANXIETY DISORDER; ARTICLE; BODY TEMPERATURE; BRAIN; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; DOPAMINERGIC SYSTEM; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; DRUG SELECTIVITY; ELECTROCONVULSIVE THERAPY; FORCED SWIMMING TEST; HIPPOCAMPUS; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; LOW DRUG DOSE; MAJOR DEPRESSION; MEMORY; MOOD; MOOD DISORDER; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPHARMACOLOGY; NONHUMAN; OBESITY; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SENSORY NERVE CELL; SEROTONINERGIC SYSTEM; THERMOREGULATION; TRANQUILIZING ACTIVITY;

EID: 56649085091     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.09.004     Document Type: Article

References (69)

1. Bandell M., et al. From chills to chilies: mechanisms for thermosensation and chemesthesis via thermoTRPs. Curr. Opin. Neurobiol. 17 (2007) 490-497
2. Cortright, D.N. and Szallasi, A. TRP channels and pain. Curr. Pharm. Des. (in press)
3. Szallasi A., and Blumberg P.M. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol. Rev. 51 (1999) 159-211
4. Szallasi A., et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 6 (2007) 357-372
5. Gavva, N. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol. Sci. (in press)
6. Jancsó-Gábor A., et al. Stimulation and desensitization of the hypothalamic heat-sensitive structure by capsaicin in rats. J. Physiol. 208 (1970) 449-459
7. Szolcsányi J., et al. Mitochondrial changes in preoptic neurons after capsaicin desensitization of the hypothalamic thermodetectors in rats. Nature 229 (1971) 116-117
8. Hori T., et al. Responses of anterior hypothalamic-preoptic thermosensitive neurons to locally applied capsaicin. Neuropharmacology 27 (1988) 135-142
9. Ritter S., and Dinh T.T. Capsaicin-induced neuronal degeneration in the brain and retina of preweanling rats. J. Comp. Neurol. 296 (1990) 447-461
10. Ritter S., and Dinh T.T. Age-related changes in capsaicin-induced neurodegeneration in rat brain. J. Comp. Neurol. 318 (1992) 103-116
11. Szolcsányi J., et al. Resiniferatoxin: an ultrapotent selective modulator of capsaicin-sensitive primary afferent neurons. J. Pharmacol. Exp. Ther. 255 (1990) 923-928
12. Caterina M.J., et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
13. Mezey E., et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3655-3660
14. Szallasi A., and Di Marzo V. New perspectives on enigmatic vanilloid receptors. Trends Neurosci. 23 (2000) 491-497
15. Cristino L., et al. Immunohistochemical localization of cannabinoid type 1 and transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139 (2006) 1405-1416
16. 3H]resiniferatoxin by human and rat preoptic area, locus ceruleus, medial hypothalamus, reticular formation and ventral thalamus membrane preparations. Life Sci. 59 (1996) 1899-1908
17. Marinelli S., et al. Activation of TRPV1 in the VTA excites dopaminergic neurons and increases chemical and noxious-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology 30 (2005) 864-870
18. Di Marzo V., et al. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homolgues. Eur. J. Pharmacol. 420 (2001) 123-131
19. Marinelli S., et al. Postsynaptic facilitation of glutaminergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J. Neurosci. 23 (2003) 3136-3144
20. Kim S.R., et al. Transient receptor potential vanilloid subtype-1 mediates cell death of mesencephalic dopaminergic neurons in vitro and in vivo. J. Neurosci. 25 (2005) 662-671
21. Starowicz K., et al. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr. Pharm. Des. 14 (2008) 42-54
22. Athanasiou A., et al. Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non vanilloid receptor-mediated cell death. Biochem. Biophys. Res. Commun. 354 (2007) 50-55
23. Di Marzo V., et al. Endovanilloid signaling in pain. Curr. Opin. Neurobiol. 12 (2002) 372-379
24. Starowicz K., et al. Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther. 114 (2007) 13-33
25. Huang S.M., et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8400-8405
26. 2+ influx via TRPV1 channels. EMBO J. 24 (2005) 3026-3037
27. Cristino L., et al. Immunohistochemical localization for anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience 151 (2008) 955-968
28. Starowicz K., et al. Tonic endovanilloid facilitation of glutamate release and brainstem descending antinociceptive pathways. J. Neurosci. 27 (2007) 13739-13749
29. Sharkey K.A., et al. Arvanil, anandamide, and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur. J. Neurosci. 25 (2007) 2773-2782
30. Marsch M., et al. Reduced anxiety, conditioned fear, and hippocampal long term potentiation in transient receptor potential vanilloid subtype 1 receptor -deficient mice. J. Neurosci. 27 (2007) 832-839
31. Gibson H.E., et al. TRPV1 channels mediate long term depression at synapses on hippocampal interneurons. Neuron 57 (2008) 746-759
32. De Petrocellis L., et al. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276 (2001) 12856-12863
33. Van Gaal L., et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients. Pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 (2008) S229-S240
34. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat. Rev. Drug Discov. 7 (2008) 438-445
35. Holderbach R., et al. Enhanced long-term synaptic depression in an animal model of depression. Biol. Psychiatry 62 (2007) 92-100
36. Levkovitz Y., et al. Transcranial magnetic stimulation and antidepressive drugs share similar cellular effects in rat hippocampus. Neuropsychopharmacology 24 (2001) 608-616
37. Stewart C.A., and Reid I.C. Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. Psychopharmacology (Berl.) 148 (2000) 217-223
38. De Murtas M., et al. Repeated electroconvulsive stimulation impairs long-term depression in the neostriatum. Biol. Psychiatry 55 (2004) 472-476
39. Deák F., et al. Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. Neuropharmacology 39 (2000) 1029-1036
40. Kasckow J.W., et al. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 291-295
41. Micale, V. et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channel. Neuropsychopharmacology (in press)
42. Mann J.J., et al. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 24 (2001) 467-477
43. Bambico F., et al. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J. Neurosci. 27 (2007) 11700-11711
44. Accorsi-Mendonca D., et al. Inhibition of spontaneous neurotransmission in the nucleus of the solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors. Brain Res. 1200 (2008) 1-9
45. Haller J., et al. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci. 19 (2004) 1906-1912
46. Martin M., et al. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl.) 159 (2002) 379-387
47. Carr R.D., et al. A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients. Atherosclerosis Supplements 9 (2008) 12
48. Gobbi G., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18620-18625
49. 1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur. J. Pharmacol. 426 (2001) R3-R4
50. Griebel G., et al. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57 (2005) 261-267
51. Pegorini S., et al. Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. Br. J. Pharmacol. 147 (2006) 552-559
52. Li, H.B. et al. Antistress effect of TRPV1 channel on synaptic plasticity and spatial memory. Biol. Psychiatry (in press)
53. Pegorini S., et al. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br. J. Pharmacol. 144 (2005) 727-735
54. Golech S.A., et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol Brain Res. 132 (2004) 87-92
55. Yamamoto S., et al. Transient receptor potential channels in Alzheimer's disease. Biochim. Biophys. Acta 1772 (2007) 958-967
56. Suri A., and Szallasi A. The emerging role of TRPV1 in diabetes and obesity. Trends Pharmacol. Sci. 29 (2008) 29-36
57. 2+-mediated mitochondrial damage and cytochrome-c release. J. Immunol. 177 (2006) 4322-4329
58. Tzavara E.T., et al. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry 59 (2006) 508-515
59. de Lago E., et al. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antiohyperkinetic agent in a rat model of Huntington's disease. Brain Res. 1050 (2005) 210-216
60. Lee J., et al. A role for vanilloid receptor (TRPV1) and endocannabinoid signaling in the regulation of spontaneous and L-DOPA-induced locomotion in normal and reserpine-treated rats. Neuropharmacology 51 (2006) 557-565
61. Morgese M.G., et al. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB1 and TRPV1 receptors. Exp. Neurol. 208 (2007) 110-119
62. Veldhuis W.B., et al. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxigenases. J. Neurosci. 23 (2003) 4127-4133
63. Rubino T., et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb. Cortex 18 (2008) 1292-1301
64. Di Marzo V., and Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 18 (2007) 129-140
65. Fowler C.J. The tools of the trade" - an overview of the pharmacology of the endocannabinoid system. Curr. Pharm. Des. 14 (2008) 2254-2265
66. Katona I., and Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 14 (2008) 923-930
67. Bliss T.V., and Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J. Physiol. 232 (1973) 331-356
68. Malberg J.E., et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20 (2000) 9104-9110
69. Santarelli L., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809